VIPhyb, an Antagonist of Vasoactive Intestinal Peptide Receptor, Enhances Cellular Antiviral Immunity in Murine Cytomegalovirus Infected Mice

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Li, Jian Ming ^a   Darlak, Kasia A ^a   Southerland, Lauren ^b   Hossain, Mohammad S ^a   Jaye, David L ^c   Josephson, Cassandra D ^a   Rosenthal, Hilary ^a   Waller, Edmund K ^a  

^a EMORY UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOMEGALOVIRUS ANTIBODY; EPITOPE; GAMMA INTERFERON; LYSYLPROPYLARGINYLARGINYLPROPYLTYROSYLASPARTYLASPARAGINYLTYROSYLTHREONYLARGINYLLYSYLGLUTAMINYLMETHIONYLALANYLVALYLLYSYLLYSYLTYROSYLLEUCYLASPARAGINYLSERYLISOLEUCYLLEUCYLASPARAGINE NH2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE ANTAGONIST; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CD8+ T LYMPHOCYTE; CELL COUNT; CELL MATURATION; CELL SUBPOPULATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; DRUG EFFECT; EFFECTOR CELL; HEPATITIS; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INTERFERON PRODUCTION; LUNG INFECTION; LYMPHOCYTE ACTIVATION; MALE; MEMORY T LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PLASMACYTOID DENDRITIC CELL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR BINDING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT DURATION; UPREGULATION; VIRAL CLEARANCE; VIRUS IMMUNITY; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; CYTOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; IMMUNITY, CELLULAR; INFLAMMATION MEDIATORS; KILLER CELLS, NATURAL; LIVER; LUNG; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; NECROSIS; NEUROTENSIN; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VASOACTIVE INTESTINAL PEPTIDE; VIRAL LOAD;

MURID HERPESVIRUS 1; MURINAE; MUS;

EID: 84878288319     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063381     Document Type: Article

References (81)

1. Boeckh M, Nichols WG, Papanicolaou G, Rubin R, Wingard JR, et al. (2003) Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant 9: 543-558.
2. Sacre K, Carcelain G, Cassoux N, Fillet AM, Costagliola D, et al. (2005) Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med 201: 1999-2010.
3. Soderberg-Naucler C, Fish KN, Nelson JA, (1997) Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91: 119-126.
4. Streblow DN, Nelson JA, (2003) Models of HCMV latency and reactivation. Trends Microbiol 11: 293-295.
5. Andrews DM, Andoniou CE, Granucci F, Ricciardi-Castagnoli P, Degli-Esposti MA, (2001) Infection of dendritic cells by murine cytomegalovirus induces functional paralysis. Nat Immunol 2: 1077-1084.
6. Farrell HE, Vally H, Lynch DM, Fleming P, Shellam GR, et al. (1997) Inhibition of natural killer cells by a cytomegalovirus MHC class I homologue in vivo. Nature 386: 510-514.
7. Farrell HE, Degli-Esposti MA, Davis-Poynter NJ, (1999) Cytomegalovirus evasion of natural killer cell responses. Immunol Rev 168: 187-197.
8. Arase H, Mocarski ES, Campbell AE, Hill AB, Lanier LL, (2002) Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296: 1323-1326.
9. Bubic I, Wagner M, Krmpotic A, Saulig T, Kim S, et al. (2004) Gain of virulence caused by loss of a gene in murine cytomegalovirus. J Virol 78: 7536-7544.
10. Smith HR, Heusel JW, Mehta IK, Kim S, Dorner BG, et al. (2002) Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc Natl Acad Sci U S A 99: 8826-8831.
11. Reeves M, Sinclair J, (2008) Aspects of human cytomegalovirus latency and reactivation. Curr Top Microbiol Immunol 325: 297-313.
12. Dowling JN, Saslow AR, Armstrong JA, Ho M, (1976) Cytomegalovirus infection in patients receiving immunosuppressive therapy for rheumatologic disorders. J Infect Dis 133: 399-408.
13. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA, (2009) The sepsis seesaw: tilting toward immunosuppression. Nat Med 15: 496-497.
14. Eddleston M, Peacock S, Juniper M, Warrell DA, (1997) Severe cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 24: 52-56.
15. Ozdemir E, St John LS, Gillespie G, Rowland-Jones S, Champlin RE, et al. (2002) Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells. Blood 100: 3690-3697.
16. McGregor A, (2010) Current and new cytomegalovirus antivirals and novel animal model strategies. Inflammation & allergy drug targets 9: 286-299.
17. Zomas A, Mehta J, Powles R, Treleaven J, Iveson T, et al. (1994) Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone marrow transplantation 14: 799-803.
18. Meyers JD, Flournoy N, Thomas ED, (1986) Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 153: 478-488.
19. Weiner RS, Bortin MM, Gale RP, Gluckman E, Kay HE, et al. (1986) Interstitial pneumonitis after bone marrow transplantation. Assessment of risk factors. Ann Intern Med 104: 168-175.
20. Reynolds RP, Rahija RJ, Schenkman DI, Richter CB, (1993) Experimental murine cytomegalovirus infection in severe combined immunodeficient mice. Lab Anim Sci 43: 291-295.
21. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL, (2000) Viral subversion of the immune system. Annu Rev Immunol 18: 861-926.
22. Hudson JB, (1979) The murine cytomegalovirus as a model for the study of viral pathogenesis and persistent infections. Arch Virol 62: 1-29.
23. Jordan MC, Takagi JL, (1983) Virulence characteristics of murine cytomegalovirus in cell and organ cultures. Infect Immun 41: 841-843.
24. Roback JD, Hossain MS, Lezhava L, Gorechlad JW, Alexander SA, et al. (2003) Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation. J Immunol 171: 6023-6031.
25. Li JM, Southerland L, Hossain MS, Giver CR, Wang Y, et al. (2011) Absence of vasoactive intestinal Peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in mice. Journal of Immunology 187: 1057-1065.
26. Li JM, Hossain MS, Southerland LT, Waller EK, (2013) Pharmacological inhibition of VIP signaling enhances antiviral immunity and improves survival in murine cytomegalovirus-infected allogeneic bone marrow transplant recipients. Blood 121: 2347-51.
27. Varela N, Chorny A, Gonzalez-Rey E, Delgado M, (2007) Tuning inflammation with anti-inflammatory neuropeptides. Expert Opin Biol Ther 7: 461-478.
28. Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, et al. (2012) Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. British journal of pharmacology 166: 4-17.
29. Eskay RL, Eiden LE, (1992) Interleukin-1 alpha and tumor necrosis factor-alpha differentially regulate enkephalin, vasoactive intestinal polypeptide, neurotensin, and substance P biosynthesis in chromaffin cells. Endocrinology 130: 2252-2258.
30. Symes A, Gearan T, Eby J, Fink JS, (1997) Integration of Jak-Stat and AP-1 signaling pathways at the vasoactive intestinal peptide cytokine response element regulates ciliary neurotrophic factor-dependent transcription. The Journal of biological chemistry 272: 9648-9654.
31. Vassiliou E, Jiang X, Delgado M, Ganea D, (2001) TH2 lymphocytes secrete functional VIP upon antigen stimulation. Arch Physiol Biochem 109: 365-368.
32. Delgado M, Pozo D, Ganea D, (2004) The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 56: 249-290.
33. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, et al. (1998) International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50: 265-270.
34. El Zein N, Badran B, Sariban E, (2008) VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1. Journal of leukocyte biology 83: 972-981.
35. Chorny A, Gonzalez-Rey E, Varela N, Robledo G, Delgado M, (2006) Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions. Regul Pept 137: 67-74.
36. Dickson L, Finlayson K, (2009) VPAC and PAC receptors: From ligands to function. Pharmacol Ther 121: 294-316.
37. Delgado M, (2009) Generating tolerogenic dendritic cells with neuropeptides. Hum Immunol 70: 300-307.
38. Delgado M, Chorny A, Gonzalez-Rey E, Ganea D, (2005) Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. Journal of leukocyte biology 78: 1327-1338.
39. Delgado M, Reduta A, Sharma V, Ganea D, (2004) VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells. Journal of Leukocyte Biology 75: 1122-1130.
40. O'Dorisio MS, Wood CL, Wenger GD, Vassalo LM, (1985) Cyclic AMP-dependent protein kinase in Molt 4b lymphoblasts: identification by photoaffinity labeling and activation in intact cells by vasoactive intestinal polypeptide (VIP) and peptide histidine isoleucine (PHI). J Immunol 134: 4078-4086.
41. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, et al. (2000) Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev 52: 269-324.
42. Turner JT, Jones SB, Bylund DB, (1986) A fragment of vasoactive intestinal peptide, VIP(10-28), is an antagonist of VIP in the colon carcinoma cell line, HT29. Peptides 7: 849-854.
43. Gozes I, Lilling G, Glazer R, Ticher A, Ashkenazi IE, et al. (1995) Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors. J Pharmacol Exp Ther 273: 161-167.
44. Moody TW, Dudek J, Zakowicz H, Walters J, Jensen RT, et al. (2004) VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice. Life Sci 74: 1345-1357.
45. Gozes Y, Brenneman DE, Fridkin M, Asofsky R, Gozes I, (1991) A VIP antagonist distinguishes VIP receptors on spinal cord cells and lymphocytes. Brain research 540: 319-321.
46. Gorham JD, Guler ML, Steen RG, Mackey AJ, Daly MJ, et al. (1996) Genetic mapping of a murine locus controlling development of T helper 1/T helper 2 type responses. Proc Natl Acad Sci U S A 93: 12467-12472.
47. Brown MG, Dokun AO, Heusel JW, Smith HR, Beckman DL, et al. (2001) Vital involvement of a natural killer cell activation receptor in resistance to viral infection. Science 292: 934-937.
48. Colwell CS, Michel S, Itri J, Rodriguez W, Tam J, et al. (2003) Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am J Physiol Regul Integr Comp Physiol 285: R939-949.
49. Hossain MS, Roback JD, Pollack BP, Jaye DL, Langston A, et al. (2007) Chronic GvHD decreases anti-viral immune responses in allogeneic BMT. Blood.
50. Hossain MS, Roback JD, Wang F, Waller EK, (2008) Host and donor immune responses contribute to antiviral effects of amotosalen-treated donor lymphocytes following early posttransplant cytomegalovirus infection. J Immunol 180: 6892-6902.
51. Biron CA, (1997) Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol 9: 24-34.
52. Giver CR, Montes RO, Mittelstaedt S, Li JM, Jaye DL, et al. (2003) Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. Biol Blood Marrow Transplant 9: 616-632.
53. Li JM, Southerland LT, Lu Y, Darlak KA, Giver CR, et al. (2009) Activation, Immune Polarization, and Graft-versus-Leukemia Activity of Donor T Cells Are Regulated by Specific Subsets of Donor Bone Marrow Antigen-Presenting Cells in Allogeneic Hemopoietic Stem Cell Transplantation. J Immunol 183: 7799-7809.
54. Delale T, Paquin A, Asselin-Paturel C, Dalod M, Brizard G, et al. (2005) MyD88-dependent and-independent murine cytomegalovirus sensing for IFN-alpha release and initiation of immune responses in vivo. J Immunol 175: 6723-6732.
55. Orange JS, Salazar-Mather TP, Opal SM, Biron CA, (1997) Mechanisms for virus-induced disease: tumor necrosis factor-mediated pathology independent of natural killer and T cells during murine cytomegalovirus infection. J Virol 71: 9248-9258.
56. Liu Z, Govindarajan S, Okamoto S, Dennert G, (2000) NK cells cause liver injury and facilitate the induction of T cell-mediated immunity to a viral liver infection. J Immunol 164: 6480-6486.
57. Benedict CA, Loewendorf A, Garcia Z, Blazar BR, Janssen EM, (2008) Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway. J Immunol 180: 4836-4847.
58. Allie SR, Zhang W, Fuse S, Usherwood EJ, (2011) Programmed death 1 regulates development of central memory CD8 T cells after acute viral infection. J Immunol 186: 6280-6286.
59. Wada J, Suzuki H, Fuchino R, Yamasaki A, Nagai S, et al. (2009) The contribution of vascular endothelial growth factor to the induction of regulatory T-cells in malignant effusions. Anticancer Res 29: 881-888.
60. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, et al. (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2: 1096-1103.
61. Banks WA, (1999) Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol 5: 538-555.
62. Rameshwar P, Gascon P, Oh HS, Denny TN, Zhu G, et al. (2002) Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor. Exp Hematol 30: 1001-1009.
63. Bopp T, Becker C, Klein M, Klein-Hessling S, Palmetshofer A, et al. (2007) Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 204: 1303-1310.
64. Lara-Marquez M, O'Dorisio M, O'Dorisio T, Shah M, Karacay B, (2001) Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol 166: 2522-2530.
65. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Ganea D, Delgado M, (2006) Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response. Blood 107: 3787-3794.
66. Delgado M, Gomariz RP, Martinez C, Abad C, Leceta J, (2000) Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock. Eur J Immunol 30: 3236-3246.
67. Collado B, Gutierrez-Canas I, Rodriguez-Henche N, Prieto JC, Carmena MJ, (2004) Vasoactive intestinal peptide increases vascular endothelial growth factor expression and neuroendocrine differentiation in human prostate cancer LNCaP cells. Regul Pept 119: 69-75.
68. Valdehita A, Carmena MJ, Collado B, Prieto JC, Bajo AM, (2007) Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells. Regul Pept 144: 101-108.
69. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034.
70. Bennett F, Luxenberg D, Ling V, Wang IM, Marquette K, et al. (2003) Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol 170: 711-718.
71. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ, (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8: 239-245.
72. Huntington ND, Tabarias H, Fairfax K, Brady J, Hayakawa Y, et al. (2007) NK cell maturation and peripheral homeostasis is associated with KLRG1 up-regulation. J Immunol 178: 4764-4770.
73. Sun JC, Beilke JN, Lanier LL, (2009) Adaptive immune features of natural killer cells. Nature 457: 557-561.
74. Delgado M, Ganea D, (2001) Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J Immunol 166: 2907-2912.
75. Abbas AK, Murphy KM, Sher A, (1996) Functional diversity of helper T lymphocytes. Nature 383: 787-793.
76. Finkelman FD, Katona IM, Mosmann TR, Coffman RL, (1988) IFN-gamma regulates the isotypes of Ig secreted during in vivo humoral immune responses. J Immunol 140: 1022-1027.
77. Sharpe AH, Freeman GJ, (2002) The B7-CD28 superfamily. Nat Rev Immunol 2: 116-126.
78. Snapper CM, Paul WE, (1987) Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. Science 236: 944-947.
79. Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, et al. (2008) Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc Natl Acad Sci U S A 105: 9331-9336.
80. Suzuki H, Onishi H, Wada J, Yamasaki A, Tanaka H, et al. (2010) VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur J Immunol 40: 197-203.
81. Sena M, Bravo DT, Von Agoston D, Waschek JA, (1994) High conservation of upstream regulatory sequences on the human and mouse vasoactive intestinal peptide (VIP) genes. DNA Seq 5: 25-29.